UniProtKB/Swiss-Prot O43734: Variant p.Asp19Asn

Adapter protein CIKS
Gene: TRAF3IP2
Chromosomal location: 6q21
Variant information

Variant position:  19
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Aspartate (D) to Asparagine (N) at position 19 (D19N, p.Asp19Asn).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to medium size and polar (N)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Psoriasis 13 (PSORS13) [MIM:614070]: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In PSORS13; there is a reducing binding of this variant to TRAF6.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  19
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  574
The length of the canonical sequence.

Location on the sequence:   MPPQLQETRMNRSIPVEV  D ESEPYPSQLLKPIPEYSPEE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 574 Adapter protein CIKS
Region 1 – 256 Mediates interaction with TRAF6
Alternative sequence 1 – 465 Missing. In isoform 4.
Alternative sequence 1 – 421 Missing. In isoform 3.


Literature citations

Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.
Huffmeier U.; Uebe S.; Ekici A.B.; Bowes J.; Giardina E.; Korendowych E.; Juneblad K.; Apel M.; McManus R.; Ho P.; Bruce I.N.; Ryan A.W.; Behrens F.; Lascorz J.; Bohm B.; Traupe H.; Lohmann J.; Gieger C.; Wichmann H.E.; Herold C.; Steffens M.; Klareskog L.; Wienker T.F.; Fitzgerald O.; Alenius G.M.; McHugh N.J.; Novelli G.; Burkhardt H.; Barton A.; Reis A.;
Nat. Genet. 42:996-999(2010)
Cited for: INVOLVEMENT IN SUSCEPTIBILITY TO PSORS13; VARIANT ASN-19; CHARACTERIZATION OF VARIANT ASN-19;

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.
Ellinghaus E.; Ellinghaus D.; Stuart P.E.; Nair R.P.; Debrus S.; Raelson J.V.; Belouchi M.; Fournier H.; Reinhard C.; Ding J.; Li Y.; Tejasvi T.; Gudjonsson J.; Stoll S.W.; Voorhees J.J.; Lambert S.; Weidinger S.; Eberlein B.; Kunz M.; Rahman P.; Gladman D.D.; Gieger C.; Wichmann H.E.; Karlsen T.H.; Mayr G.; Albrecht M.; Kabelitz D.; Mrowietz U.; Abecasis G.R.; Elder J.T.; Schreiber S.; Weichenthal M.; Franke A.;
Nat. Genet. 42:991-995(2010)
Cited for: VARIANT PSORS13 ASN-19;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.